Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)
The purpose of this study is to determine the maximum tolerated dose and/or maximum attainable dose of a vaccine consisting of human autologous dendritic cells transduced by an adenovector expressing rat Her-2/neu (AdHer-2/neu) in patients with metastatic breast cancer.
Metastatic Breast Cancer
BIOLOGICAL: AdHer-2/neu transduced dendritic cells
toxicity, weeks 4, 6, 7, 10, 14, 18, 22, 26
tumour response, Weeks 6, 18
The purpose of this study is to determine the maximum tolerated dose and/or maximum attainable dose of a vaccine consisting of human autologous dendritic cells transduced by an adenovector expressing rat Her-2/neu (AdHer-2/neu) in patients with metastatic breast cancer.